strong street estim get closer
report strong result wednesday even sale
come street forecast us omnipod
sale beat strong new patient growth season uptick pod reorder
continu strength europ drove ou beat drug deliveri came
expect repres declin guidanc
rang manag issu better expect guidanc sale forecast
includ benefit compar
street appl appl basi us omnipod
guid conserv view impli
modest new patient growth view unlik given size anima
tailwind declin pod per patient vs increas saw
view ou guid reason assum
sale follow assumpt european distribut one surpris
guidanc drug deliveri assum declin slow
onpro channel fill ahead potenti biosimilar entri later year
insulet beat driven strong out-performance us
ou omnipod busi drug deliveri fell short
us omnipod busi post beat sale
come street driver includ earli day
anima pump user convers compris new patient start
increment patient math increas amount
reorder driven higher deduct plan global omnipod instal
base grew patient growth us ou
impli us new patient growth y/i easi comp
result new patient growth year
outsid omnipod busi also impress sale
come street despit tough comp franc
impend ypsome transit estim ou new patient growth
patient sharp increas estim declin drug
deliveri sale declin y/i miss street estim
onpro neulasta mix mean less stock
need us biosimilar competit like year end start
lower product order declin expect continu
guidanc call declin drug deliveri sale
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
manag issu initi sale guidanc
includ benefit vs street doesnt addit
full year guidanc first quarter outlook came
includ half ou omnipod half drug deliveri take
page playbook view guidanc conserv insulet
beat top end guidanc everi quarter finish year
sale ahead outlook provid novemb guidanc impli
sequenti declin last year declin sequenti
specif outlook us omnipod sale ou
drug deliveri declin
us diabet patient base expect grow
intern compani expect patient base grow drug deliveri
sharp drop-off exhibit even steeper declin project mean
near-term peak drug deliveri signific pipelin
partnership disclos
look ahead guidanc call gross margin rang first
ebit-posit year compani upcom convers direct distribut
omnipod europ gross margin outlook compos follow
model direct oper europ result gross margin
region compar estim gross profit achiev
distributor ypsome us omnipod juli decis assum
direct distribut respons ypsome acceler compani toward
long-term goal compani gross margin lastli manag
reiter expect ebit-posit low-singl digit rang
higher
turn back quarter gross margin
street result margin full year oper spend sg
higher expect compani continu invest build
distribut oper europ convers came
street told led net loss per share vs street
updat estim model revenu
includ us omnipod sale ou omnipod sale
drug deliveri sale bottom-lin model
net loss model revenu
net loss
despit bullish view rel manag guidanc assign
neutral rate due strictli valuat trade
ev/sal base mid-point guidanc trade north
ev/sal smid-cap name higher-growth peer
averag growth vs trade
ev/sal ev/gross profit basi trade vs
peer best argu in-lin multipl high-growth
peer given growth outlook path
profit cant justifi premium valuat street-high estim
y/e price target valu revenu forecast
invest thesi valuat risk
come strong led robust uptak omnipod franc
quickli captur share year launch
rapidli chang competit landscap highlight js exit busi
medtron launch challeng tandem financi life support
head outlook continu look bright enjoy
extend tailwind js exit busi anima custom forc
choos new pump system get bulk patient
increment boost signific recogn exit
busi realli two good option patient view
reluct switch tandem given uncertainti surround stay power
cant make busi tandem launch next
gener dash final come late bring long await updat
omnipod date receiv allow bluetooth connect pump
cgm integr sensor busi set undergo
transform chang assum european sale respons former
distributor ypsome juli weve long argu achiev
materi profit need find differ approach europ go
direct itll access full profit omnipod final
expect drug deliveri busi increment contributor vs prior
year potenti entri biosimilar neulasta late could pressur sale
throughout year limit inventori despit bullish view rel street
expect assign neutral rate due strictli valuat
trade ev/sal base mid-point guidanc
trade north ev/sal smid-cap name
higher-growth peer averag growth vs
trade ev/sal ev/gross profit basi
trade vs peer best argu
in-lin multipl high-growth peer given
insulet growth outlook path profit cant justifi premium
valuat street-high estim y/e price target valu
revenu forecast
risk rate price
upsid risk neutral rate includ acceler new patient add
competitor johnson johnson exit busi pipelin develop insulet
non-insulin busi greater adopt insulin pump type type
downsid risk includ signific increment delay state manufactur
regulatori goal disrupt compon suppli product qualiti issu
insulet corp summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
